Participated · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Participated · Series B · Apr 2026

Ray Therapeutics is a Berkeley, California–based clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision in patients with severe retinal degenerations. Its lead program, RTx-015, is an optogenetic gene therapy delivered as a single intravitreal injection and is being evaluated in patients with retinitis pigmentosa. The company’s second clinical-stage program, RTx-021, targets retinal bipolar cells and is designed for macular diseases such as Stargardt disease and geographic atrophy (GA AMD). RayTx’s approach delivers a bioengineered, highly light-sensitive protein to targeted retinal cells with the aim of improving visual function regardless of underlying genetic mutation. The company recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for RTx-015, and it plans to use recent financing to advance late-stage clinical development and commercial readiness.

Participated · Series A · May 2025

Therini Bio is a clinical-stage biotech based in Sacramento, California developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction. Led by CEO Tara Nickerson, Ph.D., the company’s lead candidate, THN391, is a humanized monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation without affecting coagulation pathways. THN391 demonstrated activity in preclinical studies preventing vascular and neuronal degeneration in Alzheimer’s disease and retinal disease models. In a Phase 1a trial in healthy volunteers, THN391 was well-tolerated, showed no adverse hematological effects or impact on coagulation and fibrinolysis, lacked an anti-drug antibody response, and had dose-proportional pharmacokinetics with a half-life supporting monthly dosing. The company plans to use proceeds to fund Phase 1b trials of THN391 in Alzheimer’s Disease and diabetic macular edema and to support development of a fibrin/VEGF bispecific. Financially, Therini raised an additional $39M in a Series A extension, increasing its Series A total to $75M. Therini Bio develops therapeutic candidates that selectively target the inflammatory component of fibrin to treat neurological diseases such as Alzheimer’s disease and multiple sclerosis, and retinal diseases including diabetic macular edema. Its lead program is a humanized monoclonal antibody, THN391, which binds the inflammation-driving region of fibrin and—based on preclinical studies—does not impair fibrin’s role in blood clotting. The company plans to advance THN391 into clinical trials and expects to announce key safety and proof-of-mechanism clinical data by the end of 2024. Therini’s pipeline aims to provide first-in-class approaches to reduce fibrin-mediated inflammation and inhibit microglial activation in the brain. The foundational science was licensed from Katerina Akassoglou’s laboratories at the Gladstone Institutes at UCSF (and formerly UCSD). Financially, the company has raised capital including a $36M Series A and holds a NIH NIA non-dilutive grant awarded in 2021 to support its Alzheimer’s program through 2024. Therini Bio is a South San Francisco–based vascular biology company focused on discovering and developing therapeutics that target fibrin. Its lead program is a monoclonal antibody against fibrin, which the company plans to advance toward the clinic for patients with inflammatory conditions associated with vascular damage. The company was co‑founded by Dr. Katerina Akassoglou and Dan Burgess, who serves as President and CEO, and is a spin‑out from the Gladstone Institutes based on technology from Dr. Akassoglou's laboratory. Therini previously announced initial seed funding of $9.35M in 2020 led by the Dementia Discovery Fund, Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation. It has also received support from the Fast Forward program of the National Multiple Sclerosis Society. Proceeds from the latest financing will be used to accelerate development of the lead program toward clinical testing. MedaRed is a biotechnology company focused on discovering and developing therapeutics that target fibrin. The company was founded upon the work of Dr. Katerina Akassoglou of Gladstone Institutes and UCSF, who discovered molecules that reduce neuroinflammation and subsequent neuronal damage. MedaRed intends to develop those molecules into fibrin-targeting therapeutics for diseases with significant unmet clinical need. Its initial therapeutic focus is on Alzheimer’s disease and multiple sclerosis. Leadership includes acting CEO Daniel Burgess and Chief Scientific Officer Jeffrey Stavenhagen, who brings two decades of scientific leadership in biologics development. The company recently completed seed financing to support its preclinical development and advancement of its candidates.

Led · Series B · May 2025

PAQ Therapeutics is a biotechnology company focused on leveraging targeted protein degradation to suppress oncogenic KRAS signaling in cancer. Its lead candidates include PT0253, a KRAS G12D degrader, and PT0511, a pan-KRAS degrader designed to address multiple oncogenic KRAS variants. The company has initiated a first-in-human, open-label Phase 1 trial of PT0511 to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with KRAS-altered solid tumors. Proceeds from recent financing will also support the ongoing Phase 1 development of PT0253. PAQ’s platform aspires to achieve deep, selective tumor suppression while maintaining favorable safety and combinability profiles, potentially overcoming limitations of current KRAS or pan-RAS inhibitor therapies. The firm’s total Series B capital now stands at $77 million, providing a strengthened balance sheet to advance multiple clinical programs.

Led · Series A · Nov 2024

ATB Therapeutics develops first‑in‑class biologics that integrate novel enzymatic and cytotoxic functionalities into targeted antibodies. Its proprietary ATBioFarm platform enables scalable, single‑step production of antibodies that combine multiple targeting and killing domains. The company is advancing a pipeline of ‘‘weaponized’’ antibodies intended to improve efficacy and safety compared with traditional conjugates. Proceeds from the recent financing are intended to accelerate clinical development of oncology and immunology candidates and to expand the ATBioFarm technology. ATB will extend research and development operations to Ghent and continue work in Marche‑en‑Famenne, where it is setting up a pilot manufacturing facility. Leadership was strengthened as industry veteran Mark Throsby joined as Executive Chair and investor partners joined the board.